Serina Therapeutics (SER) Assets Average (2019 - 2026)
Serina Therapeutics (SER) posted Assets Average of $9.7 million for Q4 2025, down 9.32% sequentially from $10.7 million in Q3 2025, and up 36.76% YoY from $7.1 million in Q4 2024.
Serina Therapeutics (SER) Assets Average (2019 - 2026) Analysis & Trends
Serina Therapeutics has reported Assets Average for 7 years, with the latest figure at $9.7 million in Q4 2025.
- Quarterly Assets Average rose 36.76% year-over-year to $9.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.7 million (up 36.76% YoY) and the FY2025 annual result came in at $6.8 million, down 12.85% from the prior year.
- Assets Average declined to $9.7 million in Q4 2025 per SER's latest filing, from $10.7 million in the prior quarter.
- Over five years, Assets Average peaked at $10.8 million in Q2 2024 and troughed at $497000.0 in Q2 2023.
- A 5-year average of $5.7 million and a median of $4.9 million in 2021 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2024: Assets Average plunged 81.23% in 2023, then surged 2069.42% in 2024.
- Over 5 years, Assets Average stood at $2.8 million in 2021, then dropped by 5.95% to $2.6 million in 2022, then soared by 303.47% to $10.6 million in 2023, then plunged by 33.14% to $7.1 million in 2024, then soared by 36.76% to $9.7 million in 2025.
- According to Business Quant data, Assets Average over the past three periods registered $9.7 million, $10.7 million, and $7.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Serina Therapeutics | 45.80 Mn | 22.78 Mn | - | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.38 Mn |
| Dec 31, 2025 | 9.68 Mn |
| Sep 30, 2025 | 10.68 Mn |
| Jun 30, 2025 | 7.84 Mn |
| Mar 31, 2025 | 6.73 Mn |
| Dec 31, 2024 | 7.08 Mn |
| Sep 30, 2024 | 9.07 Mn |
| Jun 30, 2024 | 10.78 Mn |
| Mar 31, 2024 | 9.91 Mn |
| Dec 31, 2023 | 10.59 Mn |
| Sep 30, 2023 | 6.35 Mn |
| Jun 30, 2023 | 497,000.00 |
| Mar 31, 2023 | 1.87 Mn |
| Dec 31, 2022 | 2.62 Mn |
| Sep 30, 2022 | 2.29 Mn |
| Jun 30, 2022 | 2.65 Mn |
| Mar 31, 2022 | 2.94 Mn |
| Dec 31, 2021 | 2.79 Mn |
| Sep 30, 2021 | 2.48 Mn |
| Jun 30, 2021 | 2.85 Mn |